X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2959) 2959
erythema - chemically induced (1994) 1994
female (1834) 1834
male (1689) 1689
adult (1293) 1293
middle aged (1076) 1076
dermatology (663) 663
aged (651) 651
drug eruptions - etiology (570) 570
index medicus (536) 536
erythema multiforme - chemically induced (514) 514
animals (453) 453
adolescent (356) 356
skin - drug effects (343) 343
erythema - pathology (322) 322
skin - pathology (292) 292
dermatology & venereal diseases (279) 279
edema - chemically induced (267) 267
erythema multiforme (262) 262
time factors (243) 243
erythema (238) 238
skin (238) 238
child (233) 233
pharmacology & pharmacy (224) 224
allergy (195) 195
treatment outcome (185) 185
dose-response relationship, drug (181) 181
administration, topical (174) 174
guinea pigs (169) 169
drug eruptions - pathology (167) 167
diagnosis, differential (166) 166
erythema - drug therapy (165) 165
administration, cutaneous (163) 163
pruritus - chemically induced (158) 158
stevens-johnson syndrome - chemically induced (156) 156
antineoplastic agents - adverse effects (149) 149
oncology (142) 142
rats (141) 141
skin diseases - chemically induced (141) 141
medicine, general & internal (140) 140
patch tests (140) 140
erythema nodosum - chemically induced (139) 139
toxic epidermal necrolysis (137) 137
hand dermatoses - chemically induced (135) 135
mice (135) 135
skin tests (128) 128
chemotherapy (126) 126
child, preschool (125) 125
photosensitivity disorders - chemically induced (125) 125
therapy (120) 120
aged, 80 and over (117) 117
drug eruptions - diagnosis (115) 115
double-blind method (113) 113
young adult (113) 113
erythema - etiology (111) 111
drug hypersensitivity - etiology (109) 109
anti-bacterial agents - adverse effects (105) 105
erythema multiforme - diagnosis (104) 104
syndrome (103) 103
care and treatment (102) 102
urticaria - chemically induced (102) 102
erythema - diagnosis (101) 101
stevens-johnson syndrome - etiology (99) 99
biopsy (98) 98
infant (98) 98
risk factors (96) 96
ultraviolet rays (95) 95
exanthema - chemically induced (94) 94
rabbits (94) 94
dermatitis, contact - etiology (93) 93
erythema multiforme - pathology (93) 93
retrospective studies (90) 90
immunology (89) 89
toxicology (89) 89
pain - chemically induced (88) 88
stevens-johnson syndrome (88) 88
administration, oral (87) 87
severity of illness index (87) 87
cancer (85) 85
follow-up studies (84) 84
foot dermatoses - chemically induced (82) 82
dermatitis, allergic contact - etiology (81) 81
drugs (81) 81
anti-inflammatory agents - therapeutic use (79) 79
complications and side effects (79) 79
dermatitis (77) 77
drug therapy (77) 77
drug therapy, combination (76) 76
blister - chemically induced (75) 75
psoriasis - drug therapy (75) 75
pediatrics (73) 73
erythema - prevention & control (72) 72
inflammation (72) 72
skin - blood supply (72) 72
drug administration schedule (69) 69
stevens-johnson-syndrome (67) 67
drug hypersensitivity (66) 66
fever - chemically induced (65) 65
safety (65) 65
anti-inflammatory agents, non-steroidal - adverse effects (63) 63
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2911) 2911
French (133) 133
German (111) 111
Japanese (31) 31
Spanish (30) 30
Polish (25) 25
Russian (18) 18
Danish (11) 11
Dutch (9) 9
Portuguese (7) 7
Hebrew (4) 4
Italian (4) 4
Hungarian (3) 3
Norwegian (3) 3
Chinese (2) 2
Finnish (2) 2
Romanian (2) 2
Slovak (2) 2
Swedish (2) 2
Arabic (1) 1
Czech (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 72, Issue 2, pp. 203 - 218
There has been a rapid emergence of numerous targeted agents in the oncology community in the last decade. This exciting paradigm shift in drug development... 
Vandetanib | Panitumumab | Multikinase inhibitors | Bevacizumab | Macular eruption | Pigment changes | Paronychia | Supportive oncodermatology | Drug eruption | Sunitinib | Lapatinib | Cetuximab | Gefitinib | Vascular endothelial growth factor | Pazopanib | Dasatinib | Photosensitivity | Imatinib | Mucositis | Morbilliform | Chemotherapy | Side effects | Stomatitis | Alopecia | Disturbed wound healing | Erlotinib | Sorafenib | KIT | Monoclonal antibodies | Dry skin | Nilotinib | Drug rash | Targeted therapy | erbB receptor | Toxic erythema | Papulopustular eruption | Hyperkeratotic handefoot skin reaction | Antiangiogenic agents | Platelet-derived growth factor receptor | Ranibizumab | Small molecule | Cutaneous adverse effects | Drug reaction | Epidermal growth factor receptor inhibitors | Mucocutaneous hemorrhage | Cancer treatment | Dermatologic toxicities | BCR-ABL | Xerosis | Canertinib | Tyrosine kinase inhibitors | Dual kinase inhibitors | Adverse sequelae | Genital rash | Anticancer | HER2 | cancer treatment | small molecule | sorafenib | morbilliform | photosensitivity | lapatinib | panitumumab | xerosis | chemotherapy | METASTATIC COLORECTAL-CANCER | mucocutaneous hemorrhage | canertinib | IMATINIB-INDUCED ERYTHRODERMA | bevacizumab | side effects | drug reaction | FOOT SKIN REACTION | sunitinib | papulopustular eruption | cetuximab | imatinib | gefitinib | drug rash | alopecia | EPIDERMAL-GROWTH-FACTOR | dry skin | disturbed wound healing | ADVANCED HEPATOCELLULAR-CARCINOMA | CHRONIC MYELOGENOUS LEUKEMIA | pigment changes | paronychia | stomatitis | dual kinase inhibitors | cutaneous adverse effects | anticancer | ranibizumab | epidermal growth factor receptor inhibitors | DERMATOLOGY | hyperkeratotic hand-foot skin reaction | tyrosine kinase inhibitors | antiangiogenic agents | dermatologic toxicities | drug eruption | multikinase inhibitors | dasatinib | nilotinib | platelet-derived growth factor receptor | adverse sequelae | supportive oncodermatology | targeted therapy | genital rash | FACTOR RECEPTOR INHIBITORS | macular eruption | toxic erythema | erlotinib | pazopanib | CHRONIC MYELOID-LEUKEMIA | EYELASH TRICHOMEGALY SECONDARY | mucositis | vandetanib | vascular endothelial growth factor | PLACEBO-CONTROLLED TRIAL | monoclonal antibodies | Drug Eruptions - etiology | Molecular Targeted Therapy - adverse effects | Humans | Drug Eruptions - therapy | Mucositis - chemically induced | Dose-Response Relationship, Drug | Dermatitis, Photoallergic - etiology | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug Eruptions - diagnosis | Fusion Proteins, bcr-abl - antagonists & inhibitors | Hair Diseases - chemically induced | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Alopecia - chemically induced | Angiogenesis Inhibitors - adverse effects | Cell Membrane - drug effects | Index Medicus
Journal Article
Lupus, ISSN 0961-2033, 10/2009, Volume 18, Issue 11, pp. 935 - 940
Journal Article
Medical Clinics of North America, ISSN 0025-7125, 07/2010, Volume 94, Issue 4, pp. 711 - 725
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 01/2015, Volume 29, Issue 1, pp. 61 - 68
Journal Article
The Oncologist, ISSN 1083-7159, 05/2011, Volume 16, Issue 5, pp. 543 - 553
Journal Article
Oncology, ISSN 0030-2414, 12/2009, Volume 77, Issue 5, pp. 257 - 271
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2011, Volume 17, Issue 7, pp. 2006 - 2013
Journal Article